NEI Research News

On February 14, 2013, the U.S. Food and Drug Administration approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP).

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD).

The Argus II retinal prosthesis, developed by Second Sight, Inc., with funding from the National Eye Institute (NEI), was recognized September 8, 2011, in honor of being the 8 millionth patent issued by the United States Patent and Trademark Office.

Study estimates prevalence of vision disorders among preschool children in three ethnic groups, identifies risk factors

Treating patients with severe cases of uveitis, the fifth leading cause of vision loss in the United States, either locally with eye implants or systemically with anti-inflammatory medications improved vision similarly over two years.

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).

More than 72,000 clinical photographs illustrate age-related eye disease progression

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos.